Organic disulfides
Medchemexpress LLC Zelebrudomide (NX-2127) | 2416131-46-7 | C39H45N9O5 | 100 MG
Zelebrudomide (NX-2127) is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (BTK). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib. Zelebrudomide also catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with respective values of 25 nM and 54 nM. Additionally, it stimulates T cell activation and increases IL-2 production in primary human T Cells.
- Orally active PROTAC degrader targets Bruton's Tyrosine Kinase (BTK).
- Inhibits proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib.
- Catalyzes degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with respective values of 25 nM and 54 nM.
- Stimulates T cell activation and increases IL-2 production in primary human T Cells.
- Demonstrates potent degradation of BTK in vivo.
- Results in superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice.
Selleck Chemical LLC NX-2127-E1381-1G
NX-2127 is a unique potent inhibitor of BTK that prevents its functions by catalyzing the ubiquitylation and proteasomal degradation of BTK rather than via direct binding NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells
Selleck Chemical LLC NX-2127-E1381-25MG
NX-2127 is a unique potent inhibitor of BTK that prevents its functions by catalyzing the ubiquitylation and proteasomal degradation of BTK rather than via direct binding NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells
Selleck Chemical LLC NX-2127-E1381-5MG
NX-2127 is a unique potent inhibitor of BTK that prevents its functions by catalyzing the ubiquitylation and proteasomal degradation of BTK rather than via direct binding NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells
Selleck Chemical LLC NX-2127-E1381-100MG
NX-2127 is a unique potent inhibitor of BTK that prevents its functions by catalyzing the ubiquitylation and proteasomal degradation of BTK rather than via direct binding NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells
Medchemexpress LLC NX-2127 | 2416131-46-7 | C39H45N9O5 | 25 MG
NX-2127 is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (BTK). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib. NX-2127 catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) and stimulates T cell activation.
- Inhibits proliferation of BTK-C481S mutant TMD8 cells
- Catalyzes degradation of Ikaros (IKZF1) and Aiolos (IKZF3)
- Stimulates T cell activation and increases IL-2 production
- Potently degrades BTK in cynomolgus monkeys in vivo
- Leads to dose-proportional exposure in plasma
- Results in superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice
Medchemexpress LLC Zelebrudomide (NX-2127) | 2416131-46-7 | C39H45N9O5 | 50 MG
Zelebrudomide (NX-2127) is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (Btk). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib and appears as a light yellow to yellow solid. The compound has a molecular weight of 719.83.
- Targets Bruton's Tyrosine Kinase (Btk)
- Inhibits the proliferation of BTKC481S mutant TMD8 cells
- Catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3)
- Stimulates T cell activation
- Increases IL-2 production in primary human T cells
- Demonstrates potent degradation of BTK in cynomolgus monkeys in vivo
- Leads to superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice
Medchemexpress LLC NX-2127 | 2416131-46-7 | C39H45N9O5 | 200 MG
Zelebrudomide (NX-2127) is an orally active PROTAC degrader targeting Bruton's Tyrosine Kinase (Btk). It effectively inhibits proliferation of BTKC481S mutant TMD8 cells and catalyzes degradation of Ikaros (IKZF1) and Aiolos (IKZF3). It also stimulates T cell activation and increases IL-2 production.
- Orally active PROTAC degrader.
- Targets Bruton's tyrosine kinase (Btk).
- Inhibits BTKC481S mutant TMD8 cell proliferation (EC50 <30 nM).
- Catalyzes Ikaros (IKZF1) and Aiolos (IKZF3) degradation.
- Stimulates T cell activation; increases IL-2 production.
- Potent BTK degradation in cynomolgus monkeys in vivo.
- Superior tumor growth inhibition in WT TMD8 and C481S mutant xenograft models.
- Appearance: solid, light yellow to yellow.
- Purity: 99.72%.
Medchemexpress LLC NX-2127 | 2416131-46-7 | C39H45N9O5 | 500 MG
Zelebrudomide (NX-2127) is an orally active PROTAC degrader that targets Bruton's Tyrosine Kinase (Btk). It inhibits the proliferation of BTKC481S mutant TMD8 cells more effectively than Ibrutinib. In vivo, it demonstrates potent degradation of BTK in cynomolgus monkeys and leads to superior tumor growth inhibition in both WT TMD8 and C481S mutant xenograft models in mice.
- Inhibits proliferation of BTKC481S mutant TMD8 cells
- Catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3)
- Stimulates T cell activation and increases IL-2 production
- Demonstrates potent degradation of BTK in cynomolgus monkeys
- Leads to superior tumor growth inhibition in xenograft models in mice
Apexbio Technology LLC DIBENZYL-DISULFIDE-1G
Dibenzyl disulfide (CAS No 150-60-7) is a significant compound in biomedical research particularly in the study of oxidative stress and cell signaling pathways Originating from natural sources like Allium vegetables it is known for its potential to modulate biochemical pathways related to enzymatic antioxidant activities Research indicates its influence on the reduction of oxidative stress via the regulation of reactive oxygen species Dibenzyl disulfide exhibits common in vitro activity in the nanomolar to low micromolar range It is utilized in various applications including cell models examining cancer cell lines and animal studies exploring its pharmacological effects Additionally its role in drug screening highlights its potential as an adjunct or alternative therapeutic agent Experimental concentrations typically depend on the specific research design ensuring adaptability across different study frameworks and objectives
Medchemexpress LLC PROTAC degrader targeting Bruton's tyrosine kinase (BTK) | 2416131-46-7 | 99.7% | 719.83 | C39H45N9O5 | 10 MG
NX-2127 is an orally bioavailable PROTAC degrader that targets Bruton's tyrosine kinase (BTK). It induces proteasomal degradation of BTK, shows activity against BTK C481S resistance mutants, degrades IKZF1 and IKZF3 transcription factors, and has demonstrated cellular and in vivo preclinical activity while promoting T cell activation and IL-2 production.
- Orally bioavailable PROTAC degrader of BTK.
- Induces proteasomal degradation of BTK and reduces BTK signaling.
- Active against BTK C481S resistance mutants in cellular models.
- Degrades IKZF1 and IKZF3, providing immunomodulatory effects.
- Stimulates T cell activation and increases IL-2 production in primary human T cells.
- Demonstrated efficacy in preclinical in vivo models.
Apexbio Technology LLC DIBENZYL-DISULFIDE-500MG
Dibenzyl disulfide (CAS No 150-60-7) is a significant compound in biomedical research particularly in the study of oxidative stress and cell signaling pathways Originating from natural sources like Allium vegetables it is known for its potential to modulate biochemical pathways related to enzymatic antioxidant activities Research indicates its influence on the reduction of oxidative stress via the regulation of reactive oxygen species Dibenzyl disulfide exhibits common in vitro activity in the nanomolar to low micromolar range It is utilized in various applications including cell models examining cancer cell lines and animal studies exploring its pharmacological effects Additionally its role in drug screening highlights its potential as an adjunct or alternative therapeutic agent Experimental concentrations typically depend on the specific research design ensuring adaptability across different study frameworks and objectives
TARGETMOL CHEMICALS INC NX-2127 1MG
Also available in 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg and bulk. Please contact Fisher for quotes. NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.NX-2127 potently catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) at 25 nM and 54 nM, respectively. NX-2127 is associated with the immune system, stimulating T cell activation and increasing IL-2 production in primary human T cells. Purity 98.11%
Medchemexpress LLC 2,6-Dichlorodiphenylamine | 15307-93-4 | 99.78% | 238.11 | 100 MG
2,6-Dichlorodiphenylamine is an analogue of Diclofenac Sodium and exhibits anti-Candida albicans activity. Diclofenac Sodium is described as a potent and nonselective anti-inflammatory agent that acts as a COX inhibitor, with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells.
- Analogue of Diclofenac Sodium.
- Exhibits anti-Candida albicans activity.
- Potent and nonselective anti-inflammatory agent.
- Acts as a COX inhibitor.
Medchemexpress LLC 2,6-Dichlorodiphenylamine | 15307-93-4 | 99.8% | 238.12 | 1 ML
2,6-Dichlorodiphenylamine is an analogue of Diclofenac Sodium and demonstrates anti-Candida albicans activity. Diclofenac Sodium is a potent and nonselective anti-inflammatory agent, functioning as a COX inhibitor with IC50s of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells, respectively. This product is intended for research use only and is not sold to patients.
- Analogue of diclofenac sodium
- Demonstrates anti-Candida albicans activity
- Potent and nonselective anti-inflammatory agent
- Functions as a COX inhibitor
- High purity of 99.78%
- Causes skin irritation
- Causes serious eye irritation
- Very toxic to aquatic life with long lasting effects
- Store at 4°C, protected from light
- Avoid inhalation, contact with eyes and skin
- Avoid dust and aerosol formation
- Use in areas with appropriate exhaust ventilation